# RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer

> **NCT02161419** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 142 (actual)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Roniciclib (BAY1000394)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02161419
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07-30
- **Primary completion:** 2015-12-31
- **Final completion:** 2016-05-25
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2018-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02161419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02161419, "RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT02161419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*